3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Tuberous Sclerosis
4
Seizures
3
Lennox Gastaut Syndrome
3
Epilepsies, Myoclonic
3
Anxiety Disorders
2
Tuberous Sclerosis 2
1
Tuberous Sclerosis 1
1
Spasms, Infantile
1
Prostatic Neoplasms
1
Parasomnias
1
Pain
1
Neoplasms
1
Nausea
1
Marijuana Abuse
1
Liver Cirrhosis
1
Glioblastoma
1
Epilepsy
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chemotherapy-Induced Peripheral Neuropathy
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Pain
1
Breast Neoplasms
1
Breast Carcinoma In Situ
1
Behavior
1
Interventions
Dexamethasone
5
Palonosetron
2
Olanzapine
2
Control Groups
2
peppermint oil
1
naldemedine
1
nabiximols
1
isatuximab
1
almond oil
1
Growth Differentiation Factor 15
1
Granisetron
1
Dronabinol
1
Cannabidiol
1
Calcium Dobesilate
1
Aromatherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nausea
×
Cannabidiol
×
1 year
×
Clear all
NCT03948074
2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2
Completed
91 enrolled